Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression

Sorafenib is an anti-tumor drug widely used in clinical treatment, which can inhibit tyrosine kinase receptor on cell surface and serine/threonine kinase in downstream Ras/MAPK cascade signaling pathway of cells. Tyrosine kinase phosphorylation plays an important role in inflammatory mechanism, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaolian, Xu, Mingkun, Shen, Jiaojiao, Li, Yuqin, Lin, Shaoping, Zhu, Min, Pang, Qiongni, Tan, Xiujuan, Tang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184561/
https://www.ncbi.nlm.nih.gov/pubmed/35680841
http://dx.doi.org/10.1038/s41420-022-01073-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184561/
https://www.ncbi.nlm.nih.gov/pubmed/35680841
http://dx.doi.org/10.1038/s41420-022-01073-7

Ejemplares similares